Anzeige
Mehr »
Samstag, 04.10.2025 - Börsentäglich über 12.000 News
Innocan Pharma: Neues Medikament für den Massenmarkt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DDU5 | ISIN: SE0015244884 | Ticker-Symbol: P52
Frankfurt
03.10.25 | 15:29
0,161 Euro
-1,53 % -0,003
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NEWBURY PHARMACEUTICALS AB Chart 1 Jahr
5-Tage-Chart
NEWBURY PHARMACEUTICALS AB 5-Tage-Chart

Aktuelle News zur NEWBURY PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.08.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury85Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Melatonin Newbury 2 mg prolonged-release tablets in Finland as the first country in a Nordic registration...
► Artikel lesen
09.07.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2024 - May 2025139Quarter 3, March 2025 - May 2025Net revenue was 6 686 (1 386) tkr.EBITDA was -5 691 (-7 861) tkr.Operating cash flow was -5 787 (-10 182) tkr.Interim period, September 2024 - May 2025Net revenue was...
► Artikel lesen
16.04.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury196Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pazopanib Newbury tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals...
► Artikel lesen
NEWBURY PHARMACEUTICALS Aktie jetzt für 0€ handeln
09.04.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2024 - February 2025157Quarter 2, December 2024 - February 2025Net revenue was 12 434 (3 135) tkr.EBITDA was -973 (-4 147) tkr.Operating cash flow was -6 371 (-7 977) tkr.Interim period, September 2024 - February 2025Net...
► Artikel lesen
19.03.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals expands its portfolio with four new products157Newbury Pharmaceuticals is strengthening its distribution partnership with an existing collaborator by adding four already registered products to its portfolio. The company plans to commercialize these...
► Artikel lesen
14.03.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets176Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Macitentan Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals in...
► Artikel lesen
24.01.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules229Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first country in a Scandinavian registration procedure. Approvals...
► Artikel lesen
24.01.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2024 - November 2024155Quarter 1, September 2024 - November 2024Net revenue was 6 538 (11 185) tkr.EBITDA was -3 759 (-2 734) tkr.Operating cash flow was 4 792 (-5 678) tkr.Cash position in the end of period was 19 431 (15...
► Artikel lesen
22.01.Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets189Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Bosutinib Newbury in Norway as the first country in a Scandinavian registration procedure. Approvals in...
► Artikel lesen
23.10.24Newbury Pharmaceuticals AB: Newbury Pharmaceuticals year-end report September 2023 - August 2024302Quarter 4, June 2024 - August 2024· Net revenue was 21 123 (2 827) tkr.· EBITDA was 2 402 (-4 468) tkr.· Operating cash flow was 130 (-3 631) tkr.Year-end period, September 2023 - August 2024· Net revenue...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1